Peptide record

TPDB92097

Hymenochirin - 1B H-0 Antibacterial Anticancer Antidiabetic Antifungal Antiparasitic Antiviral Hemolysis Toxicity modified_plain modified
29 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92097
Hymenochirin - 1B H-0
Antibacterial Anticancer Antidiabetic Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cardiometabolic peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP AFP-GFuse Antifungipept CAFPdb AVPpred-BWR APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
modified_plain
Yes
A 29-aa modified multi-activity (Antibacterial, Anticancer, Antidiabetic, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
29 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial and Anticancer Host Defense Peptide Activity
Hymenochirus boettgeri Activity
Evidence Records 7 records
Evidence 1 Activity

Activity

IC50
IC50 = 15.22 ± 0.21 µM
Anticancer
15.22

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 12.76 ± 0.43 µM
Anticancer
12.76

Target

Colon Cancer
HCT-116
Colon

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 3 Activity

Activity

IC50
IC50 = 8.07 ± 0.21 µM
Anticancer
8.07

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 4 Activity

Activity

20% cell viability at 10 µM
Anticancer

Target

Lung Cancer
NCI-H-1299
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 5 Activity

Activity

40% cell viability at 10 µM
Anticancer

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 6 Activity

Activity

10% cell viability at 50 µM
Anticancer

Target

Lung Cancer
NCI-H-460
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 7 Activity

Activity

30% cell viability at 20 µM
Anticancer

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019